Analysis Of Income And Expense [Abstract]

ERYTECH Pharma S.A. - Filing #2813524

Concept	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2020-01-01 to 2020-12-31	2020-01-01 to 2020-12-31	2020-01-01 to 2020-12-31	2020-01-01 to 2020-12-31	2020-01-01 to 2020-12-31	2020-01-01 to 2020-12-31
Analysis of income and expense [abstract]
Material income and expense [abstract]
Research and development expense	—	—	—	19 907 EUR	—	—	—	—	—	—	—	45 100 EUR	—	57 580 EUR	—	—	—	—
Finance income (cost)	—	—	—	3 089 EUR	—	—	—	—	—	—	—	2 720 EUR	—	4 465 EUR	—	—	—	—
Selling, general and administrative expense [abstract]
General and administrative expense	—	—	—	13 887 EUR	—	—	—	—	—	—	—	15 595 EUR	—	14 970 EUR	—	—	—	—
Revenue and other operating income	—	—	—	30 998 EUR	—	—	—	—	—	—	—	4 180 EUR	—	3 718 EUR	—	—	—	—
Operating expense	—	—	—	33 794 EUR	—	—	—	—	—	—	—	60 695 EUR	—	72 550 EUR	—	—	—	—
Miscellaneous other comprehensive income [abstract]
Other comprehensive income, before tax, exchange differences on translation of foreign operations and hedges of net investments in foreign operations [abstract]
Other comprehensive income, before tax, exchange differences on translation of foreign operations	—	—	—	187,000 EUR	—	—	—	—	—	—	—	528,000 EUR	—	400,000 EUR	—	—	—	—
Income tax relating to components of other comprehensive income [abstract]
Income tax relating to components of other comprehensive income that will not be reclassified to profit or loss	—	—	—	— EUR	—	—	—	—	—	—	—	— EUR	—	— EUR	—	—	—	—
Comprehensive income, continuing and discontinued operations [abstract]
Comprehensive income	235,000 EUR	228,000 EUR	— EUR	194,000 EUR	— EUR	187,000 EUR	53 797 EUR	— EUR	68,000 EUR	— EUR	528,000 EUR	54 257 EUR	— EUR	72 919 EUR	400,000 EUR	— EUR	73 300 EUR	19,000 EUR